

# ANTICANCER RESEARCH

International Journal of Cancer Research and Treatment

ISSN: 0250-7005

## **Screening for Identification of Personalized Food to Promote Adiponectin Secretion in Patients with Cancer**

MIKI SAKAUE<sup>1</sup>, KAZUHISA MAEDA<sup>2</sup>, SATOSHI OHNO<sup>1</sup> and TOSHINORI ITO<sup>1</sup>

<sup>1</sup>*Department of Integrative Medicine, Osaka University Graduate School of Medicine, Osaka, Japan;*

<sup>2</sup>*Kitasenri Maeda Clinic, Suita, Japan*

*Reprinted from*

ANTICANCER RESEARCH 36: 3673-3678 (2016)

# ANTICANCER RESEARCH

International Journal of Cancer Research and Treatment



ISSN (print): 0250-7005  
ISSN (online): 1791-7530

## Editorial Board

**P. A. ABRAHAMSSON**, Malmö, Sweden  
**B. B. AGGARWAL**, Houston, TX, USA  
**T. AKIMOTO**, Kashiwa, Chiba, Japan  
**P. Z. ANASTASIADIS**, Jacksonville, FL, USA  
**A. ARGIRIS**, San Antonio, TX, USA  
**J. P. ARMAND**, Toulouse, France  
**V. I. AVRAMIS**, Los Angeles, CA, USA  
**R. C. BAST**, Houston, TX, USA  
**D.-T. BAU**, Taichung, Taiwan, ROC  
**G. BAUER**, Freiburg, Germany  
**E. E. BAULIEU**, Le Kremlin-Bicetre, France  
**E. J. BENZ, Jr.**, Boston, MA, USA  
**J. BERGH**, Stockholm, Sweden  
**F. T. BOSMAN**, Lausanne, Switzerland  
**G. BROICH**, Monza, Italy  
**Ø. S. BRULAND**, Oslo, Norway  
**J. M. BUATTI**, Iowa City, IA, USA  
**M. M. BURGER**, Basel, Switzerland  
**M. CARBONE**, Honolulu, HI, USA  
**C. CARLBERG**, Kuopio, Finland  
**J. CARLSSON**, Uppsala, Sweden  
**A. F. CHAMBERS**, London, ON, Canada  
**P. CHANDRA**, Frankfurt am Main, Germany  
**L. CHENG**, Indianapolis, IN, USA  
**J.-G. CHUNG**, Taichung, Taiwan, ROC  
**E. DE CLERCQ**, Leuven, Belgium  
**W. DEN OTTER**, Amsterdam, The Netherlands  
**E. P. DIAMANDIS**, Toronto, ON, Canada  
**G. TH. DIAMANDOPOULOS**, Boston, MA, USA  
**D. W. FELSHER**, Stanford, CA, USA  
**J. A. FERNANDEZ-POL**, Chesterfield, MO, USA  
**I. J. FIDLER**, Houston, TX, USA  
**A. P. FIELDS**, Jacksonville, FL, USA  
**B. FUCHS**, Zurich, Switzerland  
**D. FUCHS**, Innsbruck, Austria  
**G. GABBIANI**, Geneva, Switzerland  
**R. GANAPATHI**, Charlotte, NC, USA  
**A. F. GAZDAR**, Dallas, TX, USA  
**J. H. GESCHWIND**, Baltimore, MD, USA  
**A. GIORDANO**, Philadelphia, PA, USA  
**G. GITSCH**, Freiburg, Germany  
**R. H. GOLDFARB**, Guilford, CT, USA  
**L. HELSON**, Quakertown, PA, USA  
**R. M. HOFFMAN**, San Diego, CA, USA  
**S. C. JHANWAR**, New York, NY, USA  
**J. V. JOHANNESSEN**, Oslo, Norway  
**B. KAINA**, Mainz, Germany  
**P. -L. KELLOKUMPU-LEHTINEN**, Tampere, Finland  
**D. G. KIEBACK**, Schleswig, Germany  
**R. KLAPDOR**, Hamburg, Germany  
**S. D. KOTTARIDIS**, Athens, Greece  
**G. R. F. KRUEGER**, Köln, Germany  
**Pat M. KUMAR**, Manchester, UK

**Shant KUMAR**, Manchester, UK  
**O. D. LAERUM**, Bergen, Norway  
**F. J. LEJEUNE**, Lausanne, Switzerland  
**L. F. LIU**, Piscataway, NJ, USA  
**D. M. LOPEZ**, Miami, FL, USA  
**E. LUNDGREN**, Umeå, Sweden  
**Y. MAEHARA**, Fukuoka, Japan  
**J. MAHER**, London, UK  
**J. MARESCAUX**, Strasbourg, France  
**J. MARK**, Skövde, Sweden  
**S. S. MARTIN**, Baltimore, MD, USA  
**S. MITRA**, Houston, TX, USA  
**S. MIYAMOTO**, Fukuoka, Japan  
**M. MUELLER**, Villingen-Schwenningen, Germany  
**F. M. MUGGIA**, New York, NY, USA  
**M. NAMIKI**, Kanazawa, Ishikawa, Japan  
**R. NARAYANAN**, Boca Raton, FL, USA  
**K. NILSSON**, Uppsala, Sweden  
**S. PATHAK**, Houston, TX, USA  
**J.L. PERSSON**, Malmö, Sweden  
**G. J. PILKINGTON**, Portsmouth, UK  
**C. D. PLATSOUKAS**, Norfolk, VA, USA  
**A. POLLIACK**, Jerusalem, Israel  
**M. RIGAUD**, Limoges, France  
**U. RINGBORG**, Stockholm, Sweden  
**M. ROSELLI**, Rome, Italy  
**A. SCHAUER**, Göttingen, Germany  
**M. SCHNEIDER**, Wuppertal, Germany  
**A. SETH**, Toronto, ON, Canada  
**G. V. SHERBET**, Newcastle-upon-Tyne, UK  
**G.-I. SOMA**, Kagawa, Japan  
**G. S. STEIN**, Burlington, VT, USA  
**T. STIGBRAND**, Umeå, Sweden  
**T. M. THEOPHANIDES**, Athens, Greece  
**P. M. UELAND**, Bergen, Norway  
**H. VAN VLIERBERGHE**, Ghent, Belgium  
**R. G. VILE**, Rochester, MN, USA  
**M. WELLER**, Zurich, Switzerland  
**B. WESTERMARK**, Uppsala, Sweden  
**Y. YEN**, Duarte, CA, USA  
**M.R.I. YOUNG**, Charleston, SC, USA  
**B. ZUMOFF**, New York, NY, USA

**J. G. DELINASIOS**, Athens, Greece  
Managing Editor

**G. J. DELINASIOS**, Athens, Greece  
Assistant Managing Editor and  
Executive Publisher

**E. ILIADIS**, Athens, Greece  
Production Editor

**Editorial Office:** International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki 19014, Greece. Tel / Fax: +30-22950-53389.

**U.S. Branch:** Anticancer Research USA, Inc., 111 Bay Avenue, Highlands, NJ 07732, USA.

E-mails: Editorial Office: journals@iia-anticancer.org

Managing Editor: editor@iia-anticancer.org

ANTICANCER RESEARCH supports: (a) the establishment and the activities of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (IIAR; Kapandriti, Attiki, Greece); and (b) the organization of the International Conferences of Anticancer Research. The IIAR is a member of UICC. For more information about ANTICANCER RESEARCH, IIAR and the Conferences, please visit the IIAR website: [www.iia-anticancer.org](http://www.iia-anticancer.org)

**Publication Data:** ANTICANCER RESEARCH (AR) is published monthly from January 2009. Each annual volume comprises 12 issues. Annual Author and Subject Indices are included in the last issue of each volume. ANTICANCER RESEARCH Vol. 24 (2004) and onwards appears online with Stanford University HighWire Press from April 2009.

**Copyright:** On publication of a manuscript in AR, which is a copyrighted publication, the legal ownership of all published parts of the paper passes from the Author(s) to the Journal.

**Annual Subscription Rates 2016 per volume:** Institutional subscription US\$ 1,898.00 (online) or US\$ 2,277.00 (print & online). Personal subscription US\$ 897.00 (online) or US\$ 1,277.00 (print & online). Prices include rapid delivery and insurance. The complete previous volumes of Anticancer Research (Vol. 1-35, 1981-2015) are available at 50% discount on the above rates.

**Subscription Orders:** Orders can be placed at agencies, bookstores, or directly with the Publisher. (e-mail: [subscriptions@iia-anticancer.org](mailto:subscriptions@iia-anticancer.org))

**Advertising:** All correspondence and rate requests should be addressed to the Editorial Office.

**Book Reviews:** Recently published books and journals should be sent to the Editorial Office. Reviews will be published within 2-4 months.

Articles in ANTICANCER RESEARCH are regularly indexed in all bibliographic services, including Current Contents (Life Sciences), Science Citation Index, Index Medicus, Biological Abstracts, PubMed, Chemical Abstracts, Excerpta Medica, University of Sheffield Biomedical Information Service, Current Clinical Cancer, AIDS Abstracts, Elsevier Bibliographic Database, EMBASE, Compendex, GEOBASE, EMBiology, Elsevier BIOBASE, FLUIDEX, World Textiles, Scopus, Progress in Palliative Care, Cambridge Scientific Abstracts, Cancergram (International Cancer Research Data Bank), MEDLINE, Reference Update - RIS Inc., PASCAL-CNRS, Inpharma-Reactions (Datastar, BRS), CABS, Immunology Abstracts, Telegen Abstracts, Genetics Abstracts, Nutrition Research Newsletter, Dairy Science Abstracts, Current Titles in Dentistry, Inpharma Weekly, BioBase, MedBase, CAB Abstracts/Global Health Databases, Investigational Drugs Database, VINITI Abstracts Journal, Leeds Medical Information, PubsHub, Sociedad Iberoamericana de Información Científica (SIIC) Data Bases.

Authorization to photocopy items for internal or personal use, or the internal or personal clients, is granted by ANTICANCER RESEARCH, provided that the base fee of \$2.00 per copy, plus 0.40 per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, MA 01970, USA. For those organizations that have been granted a photocopy license by CCC, a separate system of payment has been arranged. The fee code for users of the Transactional Reporting Service is 0250-7005/2016 \$2.00 +0.40.

The Editors and Publishers of ANTICANCER RESEARCH accept no responsibility for the opinions expressed by the contributors or for the content of advertisements appearing therein.

Copyright© 2016, International Institute of Anticancer Research (Dr. John G. Delinasios), All rights reserved.

D.T.P. BY IIAR

PRINTED BY ENTYP0, ATHENS, GREECE. PRINTED ON ACID-FREE PAPER

# Screening for Identification of Personalized Food to Promote Adiponectin Secretion in Patients with Cancer

MIKI SAKAUE<sup>1</sup>, KAZUHISA MAEDA<sup>2</sup>, SATOSHI OHNO<sup>1</sup> and TOSHINORI ITO<sup>1</sup>

<sup>1</sup>Department of Integrative Medicine, Osaka University Graduate School of Medicine, Osaka, Japan;

<sup>2</sup>Kitasenri Maeda Clinic, Suita, Japan

**Abstract.** *Background/Aim: Adiponectin is secreted specifically from adipose tissue. Low serum adiponectin levels may cause metabolic syndrome, which is also a risk factor for carcinogenesis. Several studies have suggested a negative correlation between adiponectin and risk of cancers. This study examined the adiponectin secretion-promoting effect of food ingredients in adipose-derived stem cells (ADSCs) obtained from patients with cancer. Patients and Methods: ADSCs from 7 lifestyle disease cancer patients were differentiated into adipocytes. Subsequently, the adipocytes were treated with 49 food constituents. The adiponectin levels in cell culture supernatants were measured after 48 and 96 h. Results: Soy genistein extract, lychee low-molecular-weight polyphenol, olive extract and turmeric promoted adiponectin secretion. Conclusion: Food constituents that promoted adiponectin secretion were identified using ADSCs derived from patients. This study suggested the possibility of a new treatment approach to prevent cancer recurrence.*

Obesity is increasing around the world. It is a serious global problem. According to a global (188 countries) survey, in 2013, the proportion of adults with obesity (body mass index (BMI) >25) was 37% in men and 38% in women (1), which is about 10% more than that in 1980. The relationship between obesity and metabolic syndrome is one of the risk factors for cancer, as well as cardiovascular diseases and diabetes. Obesity is associated with the development of esophageal, pancreatic, rectal, breast and prostate cancers (2). Adiponectin is an adipocytokine secreted by adipocytes (3, 4). Several studies have suggested a negative correlation

between adiponectin and risk of cancer (5, 6). Decreased serum adiponectin is a risk factor for the development of cancers, such as breast (7, 8, 9), endometrial (10), prostate (11), colon (12) and stomach cancer (13). These cancers are known as “lifestyle disease-type cancers”. Inflammatory cytokines, such as human tumor necrosis factor (TNF)- $\alpha$  and interleukin (IL)-6, are secreted by matured adipocytes and induce insulin resistance and atherosclerosis (14-16). Interestingly, serum adiponectin levels are decreased by accumulation of visceral fat in patients with metabolic syndrome (17). Adiponectin has anti-inflammatory effects that improve glucose intolerance and dyslipidemia. Furthermore, there is also a negative correlation between the blood adiponectin concentration and development of cardiovascular diseases. Therefore, an increase in the blood adiponectin concentration may prevent the lifestyle disease associated with obesity.

Recently, dietary supplements have been widely used as one of the preventive medical approaches. However, the safety and efficacy of some supplements remains unknown.

Some food constituents may inhibit the metabolic syndrome. Yasueda *et al.* investigated the dietary anti-obesity supplements used in the Japanese market. They found clinical evidence of anti-obesity efficacy only for 11 dietary supplements (18).

Recently, we developed a screening system based on adipose-derived stem cells (ADSCs) (19) with enhanced adiponectin selection capability. In the present study, the ADSCs screening system was used to identify the drug and dietary supplement ingredients that promote adiponectin secretion.

## Patients and Methods

Adipose tissue was obtained from 7 cancer patients with lifestyle diseases during prostate, colon and pancreatic surgery (Table I). ADSCs were isolated as reported previously (20). Briefly, tissues were washed several times in phosphate buffered saline (PBS). After removal of other tissues, such as blood vessels, the adipose tissue was minced. They were digested with type 2 collagenase (0.1%, Sigma-Aldrich, St. Louis, MO, USA) solution for 1 h in a 37°C

*Correspondence to:* Toshinori Ito, MD, Ph.D., Department of Integrative Medicine, Osaka University Graduate School of Medicine, Osaka, Japan. Tel: +81 668793498, Fax: +81 668793499, e-mail: juki@cam.med.osaka-u.ac.jp

*Key Words:* Adiponectin, dietary supplements, adipose-derived stem cell, cancer, obesity.

Table I. Sources of the adipose tissue used to isolate adipose-derived stem cells (ADSCs).

	Gender	Age	BMI (kg/m <sup>2</sup> )	Cancer type
Case 1	Male	59	25.2	Prostate
Case 2	Female	42	31.4	Colon
Case 3	Male	78	24.5	Colon
Case 4	Male	64	24.9	Colon
Case 5	Male	65	25.6	Colon
Case 6	Male	63	25.4	Prostate
Case 7	Male	64	25.6	Pancreatic

water bath under constant shaking. Subsequently, the digested tissues were filtered using a mesh filter (100 µm, 70 µm and 40 µm; BD Falcon, MA, USA) and centrifuged to isolate ADSCs. The isolated ADSCs were placed in a 100-mm culture dish and incubated at 37°C in a humidified 5% CO<sub>2</sub> atmosphere. They were cultured in a pre-adipocyte medium (PM-1®, Zen-bio, Inc, NC, USA). For assay, ADSCs were placed in 96-well plates and grown to confluence. For differentiation into adipocytes, ADSCs were cultured in an adipocyte differentiation medium (DM-2, Zen-bio®). After culturing for 8 days, cells were placed in another medium (DMEM/Ham's F-12 with L-Gln, sodium pyruvate and HEPES; Nacalai Tesque Inc., Kyoto, Japan) and treated with food constituents for 48 and 96 h (Figure 1). Adiponectin levels of cell supernatants after 48 and 96 h were measured using an ELISA kit specific for human adiponectin (Otsuka Pharmaceuticals, Tokushima, Japan). In order to avoid the maturity effects of fat cells, evaluation was made by calculating a ratio of adiponectin production after 48 and 96 h (adiponectin production ratio (APR)=adiponectin after 96 h/48 h; n=49). The ethical committee of the Osaka University Hospital approved this study.

**Results**

The results of screening of 49 samples are shown in Table II. APR is referred to as 0.5<+≤1, 1.0<++. According to the APR volumes, soy genistein extract (no. 9), lychee low-molecular-weight polyphenol (no. 13), olive extract (no. 31) and turmeric (no. 45) promoted adiponectin secretion. Soy genistein promoted adiponectin secretion in 4 patients. Lychee low-molecular-weight polyphenol promoted secretion in five patients. Olive extract promoted secretion in five patients. Turmeric promoted four patients. Because of the protocol's regulations, other samples cannot be disclosed.

**Discussion**

This study screened and identified food constituents that affect adiponectin production using ADSCs obtained from cancer patients with lifestyle diseases. We have previously used the same system for screening of drugs that affect adiponectin production (19). Some drugs, such as pioglitazone hydrochloride, telmisartan, bezafibrate, sodium

Table II. Results of screening 49 samples. Items from the above list that can be disclosed due to protocol's regulations are: soy genistein extract (no. 9), lychee low-molecular-weight polyphenol (no. 13), olive extract (no. 31) and turmeric (no. 45).

Sample no.	Case 1	Case 2	Case 3	Case 4	Case 5	Case 6	Case 7
1							
2							
3				++		++	
4							
5							
6						+	+
7						+	
8							
9		+		++	+	++	
10							
11							+
12							+
13			+	+	+	+	++
14				+	+	+	
15						+	
16							
17				+	+		
18							
19				+			
20							
21						+	+
22	+	++	++		++		
23				+			
24							
25							
26							
27							
28					+		+
29							
30							+
31			+	+	++	++	++
32						+	+
33						+	
34							
35	+					+	++
36							+
37							
38							
39	+						+
40							
41				+			
42							+
43					+		
44							
45	+	++	++		++		
46	+			+	+		+
47							
48			+		+	+	+
49					+		

0.5<+≤1, 1.0<++

salt, glibenclamide, glimepiride, gliclazide, metformin and verapamil, increased adiponectin levels in the cell culture supernatants. To the best of our knowledge, this is the first




Figure 1. Study's protocol.

report of screening for food constituents exhibiting an adiponectin-promoting effect.

Results showed that soy genistein extract, lychee low-molecular-weight polyphenol, olive extract and turmeric had anti-obesity effects and enhanced adiponectin levels. Lychee low-molecular-weight polyphenol has potent antioxidant (23-26), anti-obesity (27) and anti-cancerous (28) effects. It has been suggested that treatment of high-fat-fed mice with lychee polyphenol could regulate adipocytokines' genes in adipocytes (26). It also increases the expression level of the gene encoding adiponectin. Furthermore, anticancer effect(s) and increased adiponectin have been reported after intake of olive extract (29-31). Similarly, turmeric has shown anti-obesity (32-34) and anti-cancer effects (35-38), while increasing adiponectin levels (39). The mechanism by which adiponectin exerts its anti-cancer effects has not yet been elucidated. However, the AMP-activated protein kinase signaling pathway has been reported to be important (40).

In this study, adipose tissue specimens from cancer patients with lifestyle diseases were screened. It has been reported that lower levels of adiponectin and cancer are related, particularly in patients with colon and pancreatic cancer (41-44).

Some food components screened in this study showed adiponectin-enhancing effect. The results of this study indicated that adiponectin secretion-promoting effects of food constituents vary from patient to patient. However, with the screening system used in this study, it is possible to select tailor-made food components to suit individual patients. Lastly, our screening system based on ADSCs may serve as a new therapeutic approach in the lifestyle disease-related cancer patients.

## Acknowledgements

The Authors thank the doctors at Department of Gastroenterological Surgery and Urology, Osaka University, for collecting adipose tissue.

## References

- 1 Ahmed SD, Khanam A, Sultan N, Idrees F and Akhter N: Serum adiponectin level association with breast cancer risk: evidence from a case-control study. *Asian Pac J Cancer Prev* 16: 4945-4948, 2015.
- 2 Bradford PG: Curcumin and obesity. *Biofactors* 39: 78-87, 2013.
- 3 Chen HW, Lee JY, Huang JY, Wang CC, Chen WJ, Su SF, Huang CW, Ho CC, Chen JJ, Tsai MF, Yu SL and Yang PC: Curcumin inhibits lung cancer cell invasion and metastasis through the tumor suppressor HLJ1. *Cancer Res* 68: 7428-7438, 2008.
- 4 Dalamaga M, Diakopoulos KN and Mantzoros CS: The role of adiponectin in cancer: a review of current evidence. *Endocr Rev* 33: 547-594, 2012.
- 5 Despres JP and Lemieux I: Abdominal obesity and metabolic syndrome. *Nature* 444: 881-887, 2006.
- 6 deVere White RW, Tsodikov A, Stapp EC, Soares SE, Fujii H and Hackman RM: Effects of a high dose, aglycone-rich soy extract on prostate-specific antigen and serum isoflavone concentrations in men with localized prostate cancer. *Nutr Cancer* 62: 1036-1043, 2010.
- 7 Ferroni P, Palmirotta R, Spila A, Martini F, Raparelli V, Fossile E, Mariotti S, Del Monte G, Buonomo O and Roselli M: Prognostic significance of adiponectin levels in non-metastatic colorectal cancer. *Anticancer research* 27: 483-489, 2007.
- 8 Freedland SJ, Sokoll LJ, Platz EA, Mangold LA, Bruzek DJ, Mohr P, Yiu SK and Partin AW: Association between serum adiponectin, and pathological stage and grade in men undergoing radical prostatectomy. *J Urol* 174: 1266-1270, 2005.
- 9 Fujii H, Yokozawa T, Kim YA, Tohda C and Nonaka G: Protective effect of grape seed polyphenols against high glucose-induced oxidative stress. *Biosci Biotechnol Biochem* 70: 2104-2111, 2006.
- 10 Gangehei L, Ali M, Zhang W, Chen Z, Wakame K and Haidari M: Oligonol a low molecular weight polyphenol of lychee fruit extract inhibits proliferation of influenza virus by blocking reactive oxygen species-dependent ERK phosphorylation. *Phytomedicine* 17: 1047-1056, 2010.
- 11 Ghafar MA, Golliday E, Bingham J, Mansukhani MM, Anastasiadis AG and Katz AE: Regression of prostate cancer following administration of Genistein Combined Polysaccharide (GCP), a nutritional supplement: a case report. *J Altern Complement Med* 8: 493-497, 2002.



- 12 Goktas S, Yilmaz MI, Caglar K, Sonmez A, Kilic S and Bedir S: Prostate cancer and adiponectin. *Urology* 65: 1168-1172, 2005.
- 13 Guadagni F, Roselli M, Martini F, Spila A, Riondino S, D'Alessandro R, Del Monte G, Formica V, Laudisi A, Portarena I, Palmirotta R and Ferroni P: Prognostic significance of serum adipokine levels in colorectal cancer patients. *Anticancer Res* 29: 3321-3327, 2009.
- 14 Han KH, Lee CH, Kinoshita M, Oh CH, Shimada KI and Fukushima M: Spent turmeric reduces fat mass in rats fed a high-fat diet. *Food Funct* 2015.
- 15 Inomata-Kurashiki Y, Maeda K, Yoshioka E, Fukuhara A, Imagawa A, Otsuki M and Shimomura I: Measurement of adiponectin production from differentiated metabolic stem cells. *Horm Metab Res* 42: 318-323, 2010.
- 16 Ishikawa M, Kitayama J, Kazama S, Hiramatsu T, Hatano K and Nagawa H: Plasma adiponectin and gastric cancer. *Clin Cancer Res* 11: 466-472, 2005.
- 17 Izadi V, Farabad E and Azadbakht L: Serum adiponectin level and different kinds of cancer: a review of recent evidence. *ISRN Oncol* 2012: 982769, 2012.
- 18 Kim JH, Kim OK, Yoon HG, Park J, You Y, Kim K, Lee YH, Choi KC, Lee J and Jun W: Anti-obesity effect of extract from fermented *Curcuma longa* L. through regulation of adipogenesis and lipolysis pathway in high-fat diet-induced obese rats. *Food Nutr Res* 60: 30428, 2016.
- 19 Kundu JK, Hwang DM, Lee JC, Chang EJ, Shin YK, Fujii H, Sun B and Surh YJ: Inhibitory effects of oligonol on phorbol ester-induced tumor promotion and COX-2 expression in mouse skin: NF-kappaB and C/EBP as potential targets. *Cancer Lett* 273: 86-97, 2009.
- 20 Kunnumakkara AB, Anand P and Aggarwal BB: Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. *Cancer Lett* 269: 199-225, 2008.
- 21 Lee YK, Park SY, Kim YM and Park OJ: Regulatory effect of the AMPK-COX-2 signaling pathway in curcumin-induced apoptosis in HT-29 colon cancer cells. *Ann NY Acad Sci* 1171: 489-494, 2009.
- 22 Li Y, Zhang J, Ma D, Zhang L, Si M, Yin H and Li J: Curcumin inhibits proliferation and invasion of osteosarcoma cells through inactivation of Notch-1 signaling. *FEBS J* 279: 2247-2259, 2012.
- 23 Luo Z, Zang M and Guo W: AMPK as a metabolic tumor suppressor: control of metabolism and cell growth. *Future Oncol* 6: 457-470, 2010.
- 24 Maeda K: Role of adiponectin and adipocyte fatty acid binding protein in the metabolic syndrome. *Diabetes Res Clin Pract* 77(Suppl 1): S17-22, 2007.
- 25 Mantzoros C, Petridou E, Dessypris N, Chavelas C, Dalamaga M, Alexe DM, Papadiamantis Y, Markopoulos C, Spanos E, Chrousos G and Trichopoulos D: Adiponectin and breast cancer risk. *J Clin Endocrinol Metab* 89: 1102-1107, 2004.
- 26 Mateos R, Pereira-Caro G, Bacon JR, Bongaerts R, Sarria B, Bravo L and Kroon PA: Anticancer activity of olive oil hydroxytyrosyl acetate in human adenocarcinoma Caco-2 cells. *J Agric Food Chem* 61: 3264-3269, 2013.
- 27 Matsuzawa Y, Funahashi T, Kihara S and Shimomura I: Adiponectin and metabolic syndrome. *Arterioscler Thromb Vasc Biol* 24: 29-33, 2004.
- 28 Miyahara Y, Nagaya N, Kataoka M, Yanagawa B, Tanaka K, Hao H, Ishino K, Ishida H, Shimizu T, Kangawa K, Sano S, Okano T, Kitamura S and Mori H: Monolayered mesenchymal stem cells repair scarred myocardium after myocardial infarction. *Nat Med* 12: 459-465, 2006.
- 29 Miyoshi Y, Funahashi T, Kihara S, Taguchi T, Tamaki Y, Matsuzawa Y and Noguchi S: Association of serum adiponectin levels with breast cancer risk. *Clin Cancer Res* 9: 5699-5704, 2003.
- 30 Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C, Mullany EC, Biryukov S, Abbafati C, Abera SF, Abraham JP, Abu-Rmeileh NM, Achoki T, AlBuhairan FS, Alemu ZA, Alfonso R, Ali MK, Ali R, Guzman NA, Ammar W, Anwari P, Banerjee A, Barquera S, Basu S, Bennett DA, Bhutta Z, Blore J, Cabral N, Nonato IC, Chang JC, Chowdhury R, Courville KJ, Criqui MH, Cundiff DK, Dabhadkar KC, Dandona L, Davis A, Dayama A, Dharmaratne SD, Ding EL, Durrani AM, Esteghamati A, Farzadfar F, Fay DF, Feigin VL, Flaxman A, Forouzanfar MH, Goto A, Green MA, Gupta R, Hafezi-Nejad N, Hankey GJ, Harewood HC, Havmoeller R, Hay S, Hernandez L, Husseini A, Idrisov BT, Ikeda N, Islami F, Jahangir E, Jassal SK, Jee SH, Jeffreys M, Jonas JB, Kabagambe EK, Khalifa SE, Kengne AP, Khader YS, Khang YH, Kim D, Kimokoti RW, Kinge JM, Kokubo Y, Kosen S, Kwan G, Lai T, Leinsalu M, Li Y, Liang X, Liu S, Logroscino G, Lotufo PA, Lu Y, Ma J, Mainoo NK, Mensah GA, Merriman TR, Mokdad AH, Moschandreas J, Naghavi M, Naheed A, Nand D, Narayan KM, Nelson EL, Neuhouser ML, Nisar MI, Ohkubo T, Oti SO, Pedroza A, Prabhakaran D, Roy N, Sampson U, Seo H, Sepanlou SG, Shibuya K, Shiri R, Shiue I, Singh GM, Singh JA, Skirbekk V, Stapelberg NJ, Sturua L, Sykes BL, Tobias M, Tran BX, Trasande L, Toyoshima H, van de Vijver S, Vasankari TJ, Veerman JL, Velasquez-Melendez G, Vlassov VV, Vollset SE, Vos T, Wang C, Wang X, Weiderpass E, Werdecker A, Wright JL, Yang YC, Yatsuya H, Yoon J, Yoon SJ, Zhao Y, Zhou M, Zhu S, Lopez AD, Murray CJ and Gakidou E: Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet* 384: 766-781, 2014.
- 31 Nishihira J, Sato-Ueshima M, Kitadate K, Wakame K and Fujii H: Amelioration of abdominal obesity by low-molecular-weight polyphenol (Oligonol) from lychee. *Journal of Functional Foods* 1: 341-348, 2009.
- 32 Ouchi N, Parker JL, Lugus JJ and Walsh K: Adipokines in inflammation and metabolic disease. *Nat Rev Immunol* 11: 85-97, 2011.
- 33 Petridou E, Mantzoros C, Dessypris N, Koukoulomatis P, Addy C, Voulgaris Z, Chrousos G and Trichopoulos D: Plasma adiponectin concentrations in relation to endometrial cancer: a case-control study in Greece. *J Clin Endocrinol Metab* 88: 993-997, 2003.
- 34 Renehan AG, Tyson M, Egger M, Heller RF and Zwahlen M: Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. *Lancet* 371: 569-578, 2008.
- 35 Sakurai T, Nishioka H, Fujii H, Nakano N, Kizaki T, Radak Z, Izawa T, Haga S and Ohno H: Antioxidative effects of a new lychee fruit-derived polyphenol mixture, oligonol, converted into a low-molecular form in adipocytes. *Biosci Biotechnol Biochem* 72: 463-476, 2008.

- 36 Scoditti E, Massaro M, Carluccio MA, Pellegrino M, Wabitsch M, Calabriso N, Storelli C and De Caterina R: Additive regulation of adiponectin expression by the mediterranean diet olive oil components oleic Acid and hydroxytyrosol in human adipocytes. *PLoS One* *10*: e0128218, 2015.
- 37 Shibata R, Ouchi N and Murohara T: Adiponectin and cardiovascular disease. *Circ J* *73*: 608-614, 2009.
- 38 Tomobe K, Fujii H, Sun B, Nishioka H and Aruoma OI: Modulation of infection-induced inflammation and locomotive deficit and longevity in senescence-accelerated mice-prone (SAMP8) model by the oligomerized polyphenol Oligonol. *Biomed Pharmacother* *61*: 427-434, 2007.
- 39 Wei EK, Giovannucci E, Fuchs CS, Willett WC and Mantzoros CS: Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. *J Natl Cancer Inst* *97*: 1688-1694, 2005.
- 40 Yasueda A, Ito T and Maeda K: Review: Evidence-based Clinical Research of Anti-obesity Supplements in Japan. *Immunol Endocr Metab Agents Med Chem* *13*: 185-195, 2013.
- 41 Yoon L, Liu YN, Park H and Kim HS: Olive Leaf Extract Elevates Hepatic PPAR alpha mRNA Expression and Improves Serum Lipid Profiles in Ovariectomized Rats. *J Med Food* *18*: 738-744, 2015.
- 42 Zhang J and Hochwald SN: Plasma adiponectin: a possible link between fat metabolism and pancreatic cancer risk. *J Natl Cancer Inst* *105*: 79-80, 2013.

*Received April 5, 2016*

*Revised May 12, 2016*

*Accepted May 23, 2016*

## Instructions for Authors 2016

*General Policy.* ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works in the field of cancer research that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

*NIH Open Access Policy.* The journal acknowledges that authors of NIH-funded research retain the right to provide a copy of the published manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

*Copyright.* Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

*Format.* Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

*Manuscripts.* Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding 4 printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:

(a) *First page* including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "review", "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) *Abstract* not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) *Introduction*; (d) *Materials and Methods/Patients and Methods*; (e) *Results*; (f) *Discussion*; (g) *Acknowledgements*; (h) *References*. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

*Figures.* All figures should appear at the end of the submitted document file. Once a manuscript is accepted all figures and graphs should be submitted separately in either jpg, tiff or pdf format and at a minimum resolution of 300 dpi. Graphs must be submitted as pictures made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Pages that include color figures are subject to color charges.

*Tables.* All tables should appear at the end of the submitted document file. Once a manuscript is accepted, each table should be submitted separately, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

*References.* Authors must assume responsibility for the accuracy of the references used. Citations for the reference sections of submitted works should follow the standard form of "Index Medicus" and must be numbered consecutively. In the text, references should be cited by number. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. *Anticancer Res* 1: 205-216, 1981. 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones* (O' Malley BW, Chamnes GC (eds.). New York, Plenum Publ Corp., pp 113-136, 1973.



*Nomenclature and Abbreviations.* Nomenclature should follow that given in "Chemical Abstracts", "Index Medicus", "Merck Index", "IUPAC –IUB", "Bergey's Manual of Determinative Bacteriology", The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (<http://www.gene.ucl.ac.uk/>). Approved mouse nomenclature may be obtained from <http://www.informatics.jax.org/>. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

*Clinical Trials.* Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by "ISRCTN"). Please note that there is no space between the prefix "ISRCTN" and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

*Ethical Policies and Standards.* ANTICANCER RESEARCH agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 ([www.icmje.org](http://www.icmje.org)). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard". Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

*Submission of Manuscripts.* Please follow the Instructions for Authors regarding the format of your manuscript and references.

Manuscripts must be submitted only through our online submission system at: <http://www.iiar-submissions.com/login.html>

In case a submission is incomplete, the corresponding Author will be notified accordingly.

Questions regarding difficulties in using the online submission system should be addressed to: email: [journals@iiar-anticancer.org](mailto:journals@iiar-anticancer.org)

*Galley Proofs.* Unless otherwise indicated, galley proofs will be sent to the corresponding Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Authors of online open access articles are entitled to a complimentary online annual subscription to Anticancer Research for the current year. Requests should be addressed to the Editorial Office. Galley proofs should be returned corrected to the Editorial Office by email within two days.

### ***Specific information and additional instructions for Authors***

1. Anticancer Research (AR) closely follows the new developments in all fields of experimental and clinical cancer research by (a) inviting reviews on topics of immediate importance and substantial progress in the last three years, and (b) providing the highest priority for rapid publication to manuscripts presenting original results judged to be of exceptional value. Theoretical papers will only be considered and accepted if they bear a significant impact or formulate existing knowledge for the benefit of research progress.
2. Anticancer Research will consider the publication of conference proceedings and/or abstracts provided that the material submitted fulfils the quality requirements and instructions of the journal, following the regular review process by two suitable referees. (For further information please click [here](#))
3. An acknowledgement of receipt, including the article number, title and date of receipt is sent to the corresponding author of each manuscript upon receipt. If this receipt is not received within 20 days from submission, the author should call or write to the Editorial Office to ensure that the manuscript (or the receipt) was not lost in the mail or during electronic submission.
4. Each manuscript submitted to AR is sent for review in confidence to two suitable referees with the request to return the manuscript with their comments to the Editorial Office within 12 days from receipt. If reviewers need a longer time or wish to send the manuscript to another expert, the manuscript may be returned to the Editorial Office with a delay. All manuscripts submitted to AR, are treated in confidence, without access to any person other than the Managing Editor, the journal's secretary, the reviewers and the printers.

5. All accepted manuscripts are peer-reviewed and carefully corrected in style and language, if necessary, to make presentation clear. (There is no fee for this service). Every effort is made (a) to maintain the personal style of the author's writing and (b) to avoid change of meaning. Authors will be requested to examine carefully manuscripts which have undergone language correction at the pre-proof or proof stage.
  6. Authors should pay attention to the following points when writing an article for AR:
    - The Instructions to Authors must be followed in every detail.
    - The presentation of the experimental methods should be clear and complete in every detail facilitating reproducibility by other scientists.
    - The presentation of results should be simple and straightforward in style. Results and discussion should not be combined into one section, unless the paper is short.
    - Results given in figures should not be repeated in tables.
    - Figures (graphs or photographs) should be prepared at a width of 8 or 17 cm with legible numbers and lettering.
    - Photographs should be clear with high contrast, presenting the actual observation described in the legend and in the text. Each legend should provide a complete description, being self-explanatory, including technique of preparation, information about the specimen and magnification.
    - Statistical analysis should be elaborated wherever it is necessary. Simplification of presentation by giving only numerical or % values should be avoided.
    - Fidelity of the techniques and reproducibility of the results, should be points of particular importance in the discussion section. Authors are advised to check the correctness of their methods and results carefully before writing an article. Probable or dubious explanations should be avoided.
    - Authors should not cite results submitted for publication in the reference section. Such results may be described briefly in the text with a note in parenthesis (submitted for publication by... authors, year).
    - The References section should provide as complete a coverage of the literature as possible including all the relevant works published up to the time of submission.
    - By following these instructions, Authors will facilitate a more rapid review and processing of their manuscripts and will provide the readers with concise and useful papers.
  7. Following review and acceptance, a manuscript is examined in language and style, and galley proofs are rapidly prepared. Second proofs are not sent unless required.
  8. Authors should correct their galley proofs very carefully and preferably twice. An additional correction by a colleague always proves to be useful. Particular attention should be paid to chemical formulas, mathematical equations, symbols, medical nomenclature etc. Any system of correction marks can be used in a clear manner, preferably with a red pen. Additions or clarifications are allowed provided that they improve the presentation but do not bring new results (no fee).
  9. Articles submitted to AR may be rejected without review if:
    - they do not fall within the journal's policy.
    - they do not follow the instructions to authors.
    - language is unclear.
    - results are not sufficient to support a final conclusion.
    - results are not objectively based on valid experiments.
    - they repeat results already published by the same or other authors before the submission to AR.
    - plagiarism is detected by plagiarism screening services.(Rejection rate (2015): 64%).
  10. Authors who wish to prepare a review should contact the Managing Editor of the journal in order to get confirmation of interest in the particular topic of the review. The expression of interest by the Managing Editor does not necessarily imply acceptance of the review by the journal.
  11. Authors may inquire information about the status of their manuscript(s) by calling the Editorial Office at +30-22950-53389, Monday to Friday 9.00-16.00 (Athens time), or by sending an e-mail to [journals@iiar-anticancer.org](mailto:journals@iiar-anticancer.org)
  12. Authors who wish to edit a special issue on a particular topic should contact the Managing Editor.
  13. Authors, Editors and Publishers of books are welcome to submit their books for immediate review in AR. There is no fee for this service.
- (This text is a combination of advice and suggestions contributed by Editors, Authors, Readers and the Managing Editor of AR).

Copyright© 2016 - International Institute of Anticancer Research (J.G. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.